FDA Approval of Cabozantinib - CABINET in pNET and epNET

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain are joined by Dr. Aman Chauhan, a medical oncologist specializing in neuroendocrine tumors from Sylvester Comprehensive Cancer Center in Miami.
As of April 2025, the oncology landscape has seen 10 new FDA approvals, including the recent approval of cabozantinib for neuroendocrine tumors based on the CABINET study. The discussion dived deep into the implications of this approval, the study design, and how cabozantinib fits into the treatment landscape for both pancreatic and extra-pancreatic neuroendocrine tumors.

Key topics covered in this episode include:
•⁠  ⁠The evolution of treatment options for neuroendocrine tumors
•⁠  ⁠Insights into the CABINET study design and results
•⁠  ⁠Sequencing treatment options for patients with neuroendocrine tumors
•⁠  ⁠Side effects and management strategies for cabozantinib
•⁠  ⁠The importance of personalized treatment approaches in oncology

Join us as we explore the exciting advancements in neuroendocrine tumor management and what they mean for patients and oncologists alike. Don't forget to like, subscribe, and check out our other discussions on FDA approvals, toxicity management, and conference highlights!

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠  Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more updates on oncology insights!